Joel Gonzalez, MD
Internal Medicine · Homestead, FLNPI 1902136617
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.3%), travel and lodging and gifts — rather than concentrated in one kind of arrangement. Boehringer Ingelheim International GmbH accounts for 68.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $1,491 and has fallen 83.1% since, to $252 in 2025.
Across 23 payments — averaging $94.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- AstraZeneca$179
- Astrazeneca UK Limited$165
- Sanofi US Services Inc.$125
- Johnson & Johnson$79
- Sumitomo Pharma America, Inc.$73
- plus $52 from 3 others
Across 415 payments — averaging $15,034 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2.6M
- Sanofi US Services Inc.$2.2M
- Sanofi$553K
- Boehringer Ingelheim$372K
- Modernatx, Inc.$267K
- Bausch Health US, LLC$92K
- plus $164K from 5 others
What the payments were for
- Travel & lodging$1,00146%
- Food & beverage$1,15353%
- Gifts$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 11 | $1,491 |
| AstraZeneca | 3 | $179 |
| Astrazeneca UK Limited | 1 | $165 |
| Sanofi US Services Inc. | 1 | $125 |
| Johnson & Johnson | 1 | $79 |
| Sumitomo Pharma America, Inc. | 3 | $73 |
| GSK | 1 | $24 |
| Pfizer | 1 | $18 |
| Purelife, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,164 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 268 | $205,329 |
| JanuviaSitagliptin Phosphate | 229 | $179,009 |
| OzempicSemaglutide | 147 | $141,264 |
| FarxigaDapagliflozin Propanediol | 130 | $93,908 |
| EntrestoSacubitril/Valsartan | 68 | $68,491 |
| JardianceEmpagliflozin | 77 | $63,679 |
| LinzessLinaclotide | 82 | $55,010 |
| XareltoRivaroxaban | 80 | $51,404 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 209 | $32,907 |
| JanumetSitagliptin Phos/Metformin Hcl | 43 | $30,547 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $26,284 |
| SymbicortBudesonide/Formoterol Fumarate | 111 | $25,722 |
| Spiriva HandihalerTiotropium Bromide | 51 | $25,512 |
| LovazaOmega-3 Acid Ethyl Esters | 28 | $24,765 |
| BrilintaTicagrelor | 51 | $23,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $18 | $218,100281 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $179 | $142,824292 claims |
| Johnson & JohnsonXarelto | $79 | $51,40480 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $24 | $40,28767 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Homestead
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.